Glasgow Medtech Nebu-Flow Secures £4.7M in Additional Funding
April 30, 2024, 3:32 pm
Nebu-Flow, a Glasgow-based medical device firm, has secured an additional £4.7 million in funding to advance inhaled drugs for patients with respiratory conditions. The company's nebuliser platform offers advantages over existing technologies in the global market valued at over $1 billion. The funding round, led by SCVC, a UK-based venture capital firm, and supported by Scottish Enterprise and other investors, will propel Nebu-Flow's mission to revolutionize respiratory drug delivery. Dr. Elijah Nazarzadeh, CEO, highlighted the technology's potential for targeted drug delivery to the lungs, cardiovascular, and central nervous systems. Scottish Enterprise's director, Kerry Sharp, praised Nebu-Flow's journey from university spinout to commercialization, with a team boasting expertise in inhalation drug delivery. The company's expansion plans and strong advisory board signal a promising future for Nebu-Flow in advancing respiratory treatments.